Pharming acquires patent portfolio of PPL Therapeutics

Published: 25-Aug-2004

Netherlands-based Pharming Group has acquired the patent portfolio of PPL Therapeutics to strengthen its product pipeline and protein production technology.


Netherlands-based Pharming Group has acquired the patent portfolio of PPL Therapeutics to strengthen its product pipeline and protein production technology.

Pharming has acquired 57 issued patents, including 19 in the US as well as several pending patent applications of PPL Therapeutics. Pharming has taken over certain product and technology licenses that PPL had obtained from third parties.

The patents cover: the production and purification of human recombinant fibrinogen and recombinant tissue sealant compositions and access to processes and know-how for the large scale GMP-grade purification of recombinant human fibrinogen; the production of several recombinant proteins such as Alpha-1-Antitrypsin, Bile Salt Stimulated Lipase, Extracellular Superoxide Dismutase, Alpha-lactalbumin and Factor IX; and the production technology for recombinant proteins, fusion proteins and peptides.

PPL had established this portfolio over a period of more than 15 years, but recently decided to restructure its commercial focus following a sale of the company. The financial terms of the transaction were not disclosed.

'We are pleased to be able to strengthen our recombinant fibrinogen and recombinant tissue sealant products by acquiring PPL patents and processes, which saves the company time and resources in the development of these products,' said Dr Francis Pinto, ceo of Pharming. 'In addition, this transaction significantly advances the worldwide patent position of our protein production technology along with recent agreements with Infigen and ProBio and will allow the company to actively pursue licensing and partnering opportunities.'

  

  • Companies:
  • Pharming
See more

You may also like

Ingredients

Therapeutic: leniolisib for APDS

Read more
APDS or activated phosphoinositide 3-kinase delta (PI3K∂) syndrome is an ultra-rare primary immunodeficiency disease

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  3. ChargePoint invest in a single-use manufacturing facility to expand product line The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
  4. COVID-19 still a significant risk for the immunocompromised, study finds AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
  5. Broughton receives flexible scope ISO 17025 accreditation New certification allows accreditation without prior approval

Upcoming event

ASGCT Annual Meeting 2024

7-11 May, 2024 | Meeting | Portland, OR See all

You may also like

Ingredients

Therapeutic: leniolisib for APDS

APDS or activated phosphoinositide 3-kinase delta (PI3K∂) syndrome is an ultra-rare primary immunodeficiency disease
Research & Development

Pharming enrols first patient in Ruconest COVID-19 study

It follows a study into the use of Ruconest in the prevention of severe SARS-CoV-2 infections in patients hospitalised with related severe pneumonia
Finance

Pharming to build downstream processing facility in Oss

The facility will process the starting material for the company’s Ruconest product
Regulatory

FDA approves new facility for Pharming Group biologic production

Netherlands-based pharmaceutical company has received approval to expand production of angioedema biologic in the Netherlands
Regulatory

European Commission amends Marketing Authorisation for RUCONEST to include self-administration

Pharming Group N.V. has announced that, following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has adopted the Commission Implementing Decision to amend the marketing authorisation for RUCONEST® to include self administration using the RUCONEST® Administration Kit.
Research & Development

Pharming announces completion of financing for RUCONEST North American Rights Acquisition

Pharming Group N.V. has announced that it has closed a new financing round, comprising three financial instruments and a rights issue, providing a total of €104 million before costs.
Research & Development

Pharming agrees collaboration with Shanghai Institute of Pharmaceutical Industry (SIPI)

Pharming also grants SIPI exc;usive licence to Ruconest in China
Subscribe now